Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Jurnal Farmasi Indonesia
Afifah Listiadewi
Universitas Airlangga
Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Immunology & microbiology Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
CLOVIBACTIN : STUDI LITERATUR ANTIBIOTIK BARU YANG DIHARAPKAN DAPAT MENGATASI RESISTENSI Wulida Nuril Fajriyah; Zamrotul Izzah; Eko Budi Koendhori; Afifah Listiadewi; Melisa Nur Diniah
Jurnal Farmasi Indonesia Vol 22 No 2 (2025): Jurnal Farmasi Indonesia
Publisher : Fakultas Farmasi Universitas Setia Budi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31001/jfi.v22i2.2717

Abstract

This review discusses about that Clovibactin is a new antibiotic isolated from soil samples in the state of North Carolina. Clovibactin contains eight depsipeptide residues consisting of a macrolactone ring and a linear tail. This antibiotic is active against gram-positive bacteria, including drug-resistant human pathogens such as Methicillin-resistant Staphylococcus aureus, Vancomycin-resistant enterococci, dan Mycobacterium.tuberculosis. This review aims to assess the activity of clovibactin against Mycobacterium tuberculosis. Clovibactin works by inhibiting all cell wall biosynthesis reactions that consume lipid I, lipid II, lipid IIIwall teichoic acid or undecaprenyl-pyrophosphate (C55PP). Clovibactin showed no cytotoxicity to National Institute of Health/3T3 and HepG2 cells in mammals at a dose of 100 µg/mL. Clovibactin has bactericidal properties on gram-positive bacteria. Clovibactin has an MIC of 0.5-1 µg/mL on M.tuberculosis so it has good bactericidal efficacy with low toxicity.
Co-Authors Eko Budi Koendhori, Eko Budi Melisa Nur Diniah Wulida Nuril Fajriyah Zamrotul Izzah